Statin administration survival. Statins adversely impacted survival, whereas H67D Hfe benefited survival, in SOD1G93A mice [risk ratio for statin vs. control: 1.97, 95% confidence limit (CL) = 1.35–2.86, P < 0.001; risk ratio for double transgenic vs. SOD1G93A: 0.66, 95% CL = 0.48–0.93, P = 0.016 (n = 8–13 per group); SOD1G93A control median survival = 143 days, SOD1G93A statin median survival = 132 days, double transgenic control median survival = 146 days, double transgenic statin median survival = 136 days].